Shire, 2 generics-makers settle litigation tied to Intuniv

04/26/2013 | Reuters

Shire settled all litigation with Watson Pharma and Actavis regarding its attention-deficit/hyperactivity disorder treatment Intuniv. Under the settlement, Actavis can produce and market its generic copy of the drug in the U.S. starting Dec. 1, 2014, while Watson could follow with its version 181 days after the release of Actavis' version.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA